Kazia Therapeutics Ltd (KZIA) KPIs and segments
Close on Nov 18, 2026Market cap $8.89MP/E –Yield –
KPIs & segments
Operating metrics and segments that drive Kazia Therapeutics's business
Kazia Therapeutics's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
Kazia Therapeutics's fiscal year ends June 30 — FY2025 = CY2025 (calendar year).
| Add to chart | Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
Sale of paxalisib(A$M) | 0.04 | 0.01 | 0 | 0 | ||
Licensing revenue(A$M) | 0 | 2.30 | 0 | 0 | 15.2 | |
Israel(A$M) | 0.04 | 0 | 0 | |||
KR(A$M) | 0 | 2.31 | 0 | 0 | ||
Earlier reporting (last reported 2023)3 | ||||||
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2025-11-07.
See a number that looks wrong?